Quest Diagnostics Inc vs TJX Companies Inc — how do they compare? Quest Diagnostics Inc trades at $206 (market cap $22.80B), while TJX Companies Inc trades at $150.51 (market cap $166.08B). The key difference: TJX Companies Inc is far larger — about 7.3× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.67%). Which is the better fit depends on your goals.
| DGX | TJX | |
|---|---|---|
Market Cap | $22.80B | $166.08B |
Sector | Health | Consumer Cyclical |
52-Week High | $216.02 | $168.41 |
52-Week Low | $166.42 | $121.35 |
Enterprise Value | $28.82B | $174.68B |
Dividend Yield | 1.67% | 1.28% |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
TJX trades at $150.53, down 0.54% today, with strong fundamentals including 8.63% net margin and 61.25% ROE. Recent quarters show consistent earnings beats, with Q1 2026 EPS of $1.19 surpassing the $1.02 estimate. Technical indicators signal near-term bearish pressure, but analyst consensus remains overwhelmingly bullish with an $181.80 price target. The company maintains robust cash flow from operations at $6.12B in 2025, supporting dividend payments and expansion plans.
Outlook is positive due to earnings momentum and international growth, but risks include valuation premiums (P/E 29.29) and consumer spending sensitivity. The stock offers growth potential if execution continues, though technical weakness may persist short-term.
Trailing returns across standard periods
Latest headlines on both assets
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →